Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
As the company pulls Blenrep, questions about its future will only intensify.
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.